Last reviewed · How we verify

NCT05061615

Clinico-demographic Features of Patients With Acne Vulgaris

Status unknown Last updated 29 September 2021
What this trial tests

trial in Acne Vulgaris in 150 participants. Status unknown.

Timeline
1 October 2021
Primary endpoint
31 October 2022
31 October 2022

Quick facts

Lead sponsorSohag University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 October 2021
Primary completion31 October 2022
Estimated completion31 October 2022
Sites1 location across Egypt

Conditions studied

Sponsor

Sohag University

Who can join

Adults 5 Days to 35, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Global Burden of Disease Study 2010 found that acne vulgaris is the eight most common skin disease, with an estimated global prevalence (for all ages) of 9.38%.(1) Furthermore . Acne is a chronic inflammatory process that presents with two types of lesions clinically; non-inflammatory (closed and open) and inflammatory lesions (papules ,pustules ,nodules and post inflammatory pigmentary changes).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05061615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing